Oral anticoagulation is the dominant strategy for stroke prevention in patients with nonvalvular atrial fibrillation. However, lifelong oral anticoagulation is associated with major issues including inappropriate dosing, nonadherence, and adverse effects. Therefore, efforts have been made to develop sitespecific therapy aimed to occlude the left atrial appendage, the anatomical site accountable for more than 90% of nonvalvular atrial fibrillationerelated ischemic strokes. This review focuses on the growing literature to put into perspective the risk-balance ratio of left atrial appendage occlusion. S troke prevention in patients with nonvalvular atrial fibrillation (AF) remains the focus of intense interest relating to the increasing frequency of the arrhythmia globally and its associated risk of stroke.
S
troke prevention in patients with nonvalvular atrial fibrillation (AF) remains the focus of intense interest relating to the increasing frequency of the arrhythmia globally and its associated risk of stroke. 1 Atrial fibrillation affects 6 million individuals in the United States and is predicted to increase to 12 million by 2030. 2 This growth may be a result of the aging population but also the increased and improved screening mechanisms. Among patients admitted with acute ischemic stroke in the United States, 18.2% have AF and this prevalence increases to 40% in patients older than 85 years. 2 Oral anticoagulation (OAC) has been the dominant strategy for stroke prevention in this setting because of its well-documented efficacy. However, there have been considerable problems with OAC including inadequate therapeutic anticoagulation, nonadherence, and issues related to under-or overdosing in selected patient subsets and with factors precluding its administration such as severe bleeding. 1 Accordingly, efforts have been made to develop site-specific therapy aimed to occlude the left atrial appendage (LAA), which is found to be the locus of thrombus in more than 90% of cases. 3 An expanding literature has become available on the feasibility and effectiveness of various LAA occlusion strategies including endocardial and epicardial strategies. 4 This review focuses on the accumulating data from both randomized clinical trials (RCTs) and large-scale registries, both from the United States and globally, to put into perspective the risk-balance ratio of LAA occlusion.
BACKGROUND
Atrial fibrillationerelated strokes are associated with higher morbidity, mortality, and cost than non-AF related strokes. 2, 5 The 2016 European Society of Cardiology (ESC) Guidelines reiterate the central role of OAC for patients with nonvalvular AF at an increased risk of stroke (class I indication; level of evidence A) and the preference to use direct oral anticoagulant (DOAC) over vitamin K antagonists in these patients. 6 However, these guidelines do not take into consideration the unmet needs in actual clinical practice, specifically the fact that OACs are either not administered, not continued, or not optimal in many patients.
UNMET CLINICAL NEEDS
Patterns of care for patients with AF who are felt to be candidates for anticoagulation were assessed in several cohort studies, which universally reported poor adherence to guideline-recommended antithrombotic therapy for stroke prevention. These dismal adherence rates persisted even in high-risk patients, across different countries, with different OAC regimens (warfarin vs DOACs) and despite quality improvement initiatives. [7] [8] [9] [10] In a large quality improvement registry of 429,417 outpatients with AF in whom OAC is indicated, only 45% were prescribed an oral anticoagulant. Even in higher-risk patients with a CHADS 2 However, despite these efforts, adherence at 1 year increased from 68% to only 80%.
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The association between the lack of OAC and the high incidence of stroke in patients with AF has been confirmed in several studies. In a study by Mazurek et al, 10 the lack of OAC was associated with an increased incidence of first stroke (odds ratio [OR], 2.95; P¼.013). Similarly, the lack of OAC was also associated with an increased risk of recurrent stroke (OR, 2.80; P¼.012) and all-cause death (OR, 2.75; P¼.006). The increased risk of stroke is evident even when OAC is not taken for a short period (1-3 months: hazard ratio [HR], 1.96; 3-6 months: HR, 2.64; !6 months: HR, 3.66; P<.001 for all). 9 In addition, antithrombotic therapy is associated with better outcomes in patients with AF who suffer a stroke despite OAC. This was illustrated in a study from the Get With the Guidelines registry, which included 94,478 patients presenting with acute ischemic stroke. 13 In this study, 83.6% of patients were not receiving therapeutic anticoagulation (39.9% treated with antiplatelet therapy only, 30.3% not treated with any antithrombotic therapy, and 13.5% had subtherapeutic warfarin anticoagulation). An adjusted analysis documented that stroke severity and in-hospital mortality were both lower in patients receiving therapeutic warfarin and DOAC compared with all other patient groups. 13 The importance of specific patient subsets has also been investigated. Yao et al 14 evaluated 14,865 patients with AF and renal insufficiency in whom a DOAC (apixaban, dabigatran, or rivaroxaban) was initiated using the dosing recommended by the manufacturer's instruction for use for each agent. This study found that among patients with a renal indication for dose reduction (n¼1473), 43% were overdosed, and this was associated with a 2-fold increase in major bleeding events. In contrast, among patients who had no renal indication for dose reduction (n¼13,392), 13.3% were underdosed, and this was associated with a 5-fold increase in the occurrence of ischemic strokes. These findings suggested that in routine clinical practice, prescribed DOAC doses are often inconsistent with drug labeling, and that these prescribing patterns may be associated with worse safety and efficacy in patients with renal insufficiency.
These unmet clinical needs with delivery of care using OACs for stroke prevention have been the impetus for the development of alternative strategies. Local site-specific therapy was first proposed in 1996 after a landmark study by Blackshear 3 suggested that the LAA may be the nidus for stroke-causing emboli from the left atrium in 91% patients with nonvalvular AF (Figure 2A) . 15, 16 This hypothesis was further tested and confirmed with the PROTECT AF (WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients With Atrial Fibrillation) trial. In this trial, a site-specific therapy (Watchman LAA occlusion device, Boston Scientific) was found to be noninferior to systemic anticoagulation with warfarin with regard to stroke, systemic embolism, and cardiovascular mortality ( Figure 2B ). 17 Since then, a plethora of data has emerged on the feasibility, safety, and effectiveness of LAA occlusion with the Watchman and other devices.
LEFT ATRIAL APPENDAGE OCCLUSION Randomized Clinical Trials
Percutaneous LAA occlusion has now been evaluated in RCTs, continued access registries, and large multicenter global registries. To date, 2 RCTsdPROTECT AF (Clinical Trials.gov identifier: NCT00129545) and Evaluation of the WATCHMAN Left Atrial Appendage (LAA) Closure Device in Patients with Atrial Fibrillation Versus Long Term Warfarin Therapy (ClinicalTrials.gov identifier: NCT01182441)dhave rigorously assessed the safety and effectiveness of LAA occlusion with the Watchman device. From these trials, long-term (5-year) outcomes and cost-effectiveness data as well as data on patient's quality of life are now available. [18] [19] [20] Both trials randomized patients with nonvalvular AF at risk of stroke or systemic embolism in a 2:1 fashion to warfarin. The selection of warfarin for OAC in the control arm has been a source of criticism in light of the availability and increased use of DOACs; however, when these RCTs were conceived and performed, DOACs were either in development or not widely used. In the control arm, warfarin was prescribed indefinitely (target international normalized ratio, 2.5-3.0). In the device arm, aspirin and warfarin were administered for 6 weeks postprocedure to optimize endothelial coverage of the device. At 45 days, patients continued aspirin, discontinued warfarin, and initiated clopidogrel for a total of 6 months postprocedure. After that, a transesophageal echocardiography study was performed: If successful device closure was documented (defined as residual leak <5 mm), only aspirin was used and continued indefinitely. In the patient-level meta-analysis of these 2 trials (1114 patients), the composite of stroke, systemic embolism, or cardiovascular or unexplained death occurred with a similar frequency in both the device and control arms (HR, 0.82; 95% CI, 0.58-1.17; P¼.27). 18 Nonetheless, there was a marked reduction in hemorrhagic stroke (HR, 0.2; 95% CI, 0.07-0.56; P¼.002), cardiovascular or unexplained death (HR, 0.59; 95% CI, 0.37-0.94; P¼.027), all-cause death (HR, 0.73; 95% CI, 0.54-0.98; P¼.035), and major nonprocedural bleeding (HR, 0.48; 95% CI, 0.32-0.71; P¼.0003) (Figure 3) . Notably, there was a trend of increased ischemic stroke in the device arm (1.6 per 100 patient-years vs 0.95 per 100 patient-years; HR, 1.71; 95% CI, 0.94-3.1; P¼.08), but this difference was attenuated when early procedure-related strokes (primarily due to air emboli introduced into the delivery system) were removed (1.3 per 100 patient-years vs 0.95 per 100 patientyears; HR, 1.4; 95% CI, 0.76-2.59; P¼.28). Although residual flow around these devices was common (32% at 1-year in PROTECT AF), small leaks less than 5 mm were not associated with excess adverse events. 21 Although there were numerically more ischemic strokes in the device arm, the device treatment group experienced a significant 55% reduction in disabling or fatal strokes (0.44 per 100 patient-years vs 1.0 per 100 patient-years; HR, 0.45; 95% CI, 0.21-0.94; P¼.03), primarily driven by the greater number of hemorrhagic strokes in the warfarin treatment group. 18 These randomized data were confirmed in the Continued Access Registry of the PROTECT AF trial, which included 566 patients with a mean follow-up of 52 months. 22 The primary safety and efficacy end points were similar to those in the main trial. Although patients in the registry were at a slightly higher risk than those in PROTECT AF (CHA 2 DS 2 -VASc score, 3.9AE1.5 vs 3.5AE1.6), the registry documented a similar dramatic reduction in hemorrhagic stroke and cardiovascular or unexplained death in the device arm compared with the warfarin arm of the predicate RCT.
On the basis of the totality of these data, the Food and Drug Administration approved the Watchman device in patients with nonvalvular AF who (1) have an indication for OAC for stroke prevention, (2) are able to tolerate short-term OAC, and (3) have an appropriate rationale to seek a nonpharmacologic alternative. In some patients, the appropriate rationale may be the presence of falls, poor adherence to medications, or lifestyle considerations. Furthermore, a shared decisionmaking process is required by an independent physician to provide evidence to the patient about their individual risks and benefits of OAC and allow the patient the opportunity to discuss their values and preferences for treatment. In contrast to the US indication, which restricts LAA occlusion to OACeligible patients, the procedure is offered to patients at an increased risk of stroke who are either eligible or ineligible for OAC outside the United States. In addition, although only the Watchman device is approved in the United States, several other devices are available under CE mark in Europe. Hence, by virtue of differences in indications, clinical practice patterns, and devices available, data from the European experience with LAA occlusion have important applications. The European data are based on nonrandomized registries. Nonetheless, these registries had a robust design that incorporated good ascertainment and follow-up methodology and enrolled a large number of patients. Hence, data afforded by these registries are valuable in the field of LAA occlusion for stroke prevention. Procedural success was high (98.5%), and serious adverse events within the first 7 days were uncommon (2.8%). At the time of discharge, warfarin was prescribed in 16% only, dual antiplatelet therapy in 60%, and single antiplatelet therapy in 7%. At 1 year, the observed rate of ischemic stroke was 84% lower than the expected rate on the basis of CHA 2 DS 2 -VASc score. The observed rate of bleeding excluding procedural bleeding was also 54% lower than what was expected when treated with warfarin on the basis of the HAS-BLED score. As a result of these data, the device instructions for use were modified to allow a flexible strategy for postimplant antithrombotic medications on the basis of individual patient situations.
Nonrandomized Registries
The ASA Plavix Feasibility Study with WATCHMAN Left Atrial Appendage Closure Technology registry (ClinicalTrials.-gov identifier: NCT00851578) studied the issue of Watchman implantation in patients in whom OAC is contraindicated. Reasons for contraindication included history of bleeding (93%), blood dyscrasias (7.3%), and falls or other risks (9.3%). The registry enrolled highrisk patients (CHA 2 DS 2 -VASc score, 4.4AE1.7). At a follow-up of 176.9 patientyears, stroke or systemic embolism occurred in 4 patients (2.3 per 100 patient-years), hemorrhagic stroke in 1 patient (0.6 per 100 patient-years), and ischemic stroke in 3 patients (1.7 per 100 patient-years). When compared with the predicted ischemic stroke rate, there was a 77% reduction in ischemic events. 24 These results led to an update of the ESC guidelines to recommend LAA occlusion for patients at a high risk of stroke and contraindications for long-term OAC. Additional follow-up was reported after 55.4 months, and the results remained consistent; ischemic stroke or systemic embolism occurred at a rate of 1.8 per Other national and international registries have also reported early and mid-term results of LAA occlusion in various cohorts of patients and by using a mixture of different LAA occlusion devices. 4 In addition, several randomized and nonrandomized trials are currently underway to assess new LAA occlusion devices and to address specific issues with the currently available devices. 4 It is worth noting that there is a paucity of societal guidelines on LAA occlusion. The 2016 ESC guidelines assigns a level IIB recommendation (level of evidence B) for LAA occlusion in patients with AF and contraindications for long-term anticoagulant treatment (eg, those with a previous lifethreatening bleed without a reversible cause). 6 There are to date no specific recommendations by professional societies in the United States on the use of LAA occlusion devices.
CURRENT CONSIDERATIONS Safety
Percutaneous placement of an LAA occlusion device typically requires a large-bore venous access, general anesthesia, and transseptal puncture of left atrial access. In addition, the current devices use stabilizing wires (barbs) to ensure device stability, but this might lead to pericardial effusions due to the thin wall of the LAA. Thus, the safety of device placement has been a cause of concern since the initial 2 RCTs and the subsequent registries. In the PROTECT AF trial, procedurerelated safety events (pericardial effusion, stroke, or device embolization) occurred in 7.0% of patients, but this was decreased to 2.7% of patients in the Continuous Access Registry, suggesting a significant improvement in procedural safety with increased operator experience. 22 This was further confirmed with subsequent examination of the posteFood and Drug Administration approval experience with the Watchman device in the United States, which documented high device implant success (95.6%) and low rates of major complications: pericardial tamponade (1%), procedure-related stroke (0.078%), device embolization (0.24%), and procedure-related death (0.078%), with 50% of the procedures performed by new operators. 26 Most recently, the US WATCHMAN New Enrollment Post Approval Surveillance Analysis Plan has evaluated real-world safety outcomes in 1000 eligible patients undergoing WATCHMAN implantation as included in the National Cardiovascular Data Registry Left Atrial Appendage Occlusion Registry (Figure 4 ). Patients were older and had higher baseline stroke and bleeding risks than in RCTs: age was 76.5AE8.1 years, CHA 2 DS 2 -VASc score was 5.0AE1.4, and HAS-BLED (hypertension, abnormal renal/liver function [one or two points], stroke, bleeding history or predisposition, labile international normalized ratio, elderly [>65 years], drugs/ alcohol concomitantly [one or two points]) score was 2.7AE1.0. The composite primary safety end point event rate was 1.49% (14 events in 941 patients; P¼.0003), well below the upper CI of the prespecified performance goal of 3.36%, and compares favorably with the rates observed in previous trials. 27 
Adjunctive Therapy
The instruction for use of antithrombotic therapy after LAA occlusion differs between the United States and Europe. In the United States, patients have to be able to take shortterm anticoagulation with warfarin for at least 45 days after LAA occlusion in an attempt to improve endothelialization of the device and prevent thrombus formation, whereas patients can be prescribed warfarin, DOACs, or antiplatelet therapy after LAA occlusion in Europe, a practice that is supported with limited observational data. 28, 29 To assess the use of various antithrombotic regimens after LAA occlusion with the Watchman device, a multicenter randomized trial (Assessment of the WATCHMAN Device in Patients Unsuitable for Oral Anticoagulation; ClinicalTrials.gov identifier: NCT02928497) was initiated. In this trial, patients are randomized in a 2:1 fashion to receive warfarin vs non-OAC with best medical therapy (single or dual antiplatelet therapy or no therapy). Data from this trial are hoped to provide a definitive answer to the issue of the need for periprocedural warfarin after LAA occlusion with the Watchman device. 30 
Cost-Effectiveness
Beyond the safety and efficacy of LAA occlusion for stroke prevention, it is important that this minimally invasive mechanical solution exhibits a savings to the health care system in terms of budget impact on national payment systems as well as cost-effectiveness compared with pharmacological options. Using data from the pivotal LAA occlusion trials, Reddy et al 31 found that LAA occlusion was cost-effective at 7 years compared with warfarin while a markedly longer time (16 years) was needed to reach costeffectiveness for DOACs compared with warfarin. Not only was mechanical closure more cost-effective but also was cost saving as compared with DOACs after 5 years and warfarin after 10 years. The costeffectiveness of LAA occlusion persisted even when the cost of the procedure is doubled. In another focused analysis in patients with previous strokes, LAA occlusion achieved cost-effectiveness relative to dabigatran at year 5 and warfarin and apixaban at year 6. 20 At 10 years, LAA occlusion had more quality-adjusted life years and lower costs than did warfarin, dabigatran, apixaban, and rivaroxaban ($42,616 vs $53,770, $58,774, $55,656, and $58,655, respectively), and these results persisted in a secondary lifetime cost-effectiveness analysis. Finally, a budget impact model derived from both a Medicare and a patient perspective found that after 5 years, LAA occlusion was the lowest cost therapy in terms of patient out-of-pocket costs and was least costly to Medicare by year 10 when compared with both warfarin (15% lower) or DOACs (48% lower). 32 
Residual Leak
Given the variability in the shape and size of the LAA and the fact that the orifice is typically oval while the devices are round, the potential for incomplete LAA occlusion and residual peridevice leaks has been of concern. 33 In the surgical literature, incomplete LAA exclusion with surgical techniques is associated with thromboembolic events during follow-up. 34, 35 In the field of percutaneous LAA occlusion, specific but arbitrary criteria have been set to define significant leak ranging from less than 1-mm to less than 5-mm residual flow on color flow Doppler interrogation with transesophageal echocardiography. In the PROTECT AF trial, evidence of peri-device flow was present in 41%, 34%, and 32% of patients at 45-day, 6-month, and 1-year follow-up. 21 At 45 days, the size of the leak was minor (<1 mm) in 8%, moderate (1-3 mm) in 60%, and major (>3 mm) in 32% of patients. However, there was no difference in ischemic events among patients with no, mild, moderate, or major leaks even among patients who discontinued OAC, suggesting that residual leak does not affect future ischemic events. Nonetheless, the low event rate limits the confidence of this conclusion. Current instructions for use consider leaks greater than 5 mm significant and hence require continuation of OAC if such a leak persists. Alternatively, percutaneous leak closure can be performed with good safety and success. 36, 37 Device-Associated Thrombus Device thrombosis is a newly recognized worrisome complication of LAA occlusion. In the Watchman RCTs, patients were mandated to receive OAC for 6 weeks after device implantation, and dual antiplatelet therapy for 6 months postimplantation to enhance endothelialization and minimize the chance of thrombus formation on the surface of the implant. Despite that, several studies have reported the device-related thrombus formation in w4% of patients during routine echocardiographic surveillance. 38, 39 The presence of device-related thrombus was associated with a 3-to 4-fold increase in ischemic events compared with patients with no devicerelated thrombus identified. Specific clinical and procedural factors (previous stroke, CHA 2 DS 2 -VASc score, permanent AF, deep device implantation, etc) were associated with thrombus formation. Because of the small number of events, an association between certain postprocedural antithrombotic regimens and device-related thrombus formation could not be ascertained. In patients with device-related thrombus, short-term anticoagulation has been found to be effective in resolving the thrombus in most cases. A particular challenging and unanswered question is the optimal length, frequency, and method of surveillance in these patients, especially considering that many of the reported devicerelated thrombosis have been reported beyond 6 months after the procedure.
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ROLE OF NEW ENDOCARDIAL LAA OCCLUSION DEVICES
The Watchman device is currently the only endocardial LAA occlusion device approved in the United States. However, a total of 7 devices have received CE mark in Europe and several other ones are undergoing clinical or preclinical evaluation. 4 The AMPLATZER family of devices (first generation: AMPLAT-ZER Cardiac Plug [ACP] and second generation: Amulet, Abbott) is the furthest along the US regulatory path. Both devices have been assessed in large multicenter registries in Europe (ACP and Amulet registries), and the Amulet device is currently undergoing a head-to-head comparison with the Watchman device in a multinational RCT. 4 The ACP device was assessed in the retrospective international ACP registry, which enrolled 1047 patient treated at 22 centers. The mean CHA 2 DS 2 -VASc score was 4.5AE1.6, and the mean HAS-BLED score was 3.1AE0.5; 47% of patients were referred for LAA occlusion because of major bleeding. Device implantation was successful in 97.3%, and major periprocedural adverse events occurred in 5% of patients, including cardiac tamponade in 1.24%, major bleeding in 1.24%, stroke in 0.86%, and death in 0.76%. 42 During a mean follow-up of 13 months, the annual rate of stroke or systemic thromboembolism was 2.3%, which represented a 59% risk reduction compared with what had been predicted from the baseline CHA 2 DS 2 -VASc score. After the procedure, most patients were treated with aspirin as monotherapy or in combination with clopidogrel, rather than with an OAC.
These excellent outcomes persisted in highrisk subgroups of patients enrolled in this registry including patients older than 75 years, those with previous gastrointestinal tract or intracranial bleeding, and those with renal insufficiency. [43] [44] [45] [46] The Amulet device was evaluated in the Global Amulet Observational Study, 47 which included 1088 high-risk patients (CHA 2 DS 2 -VASc score, 4.2AE1.6) treated at 61 centers between 2015 and 2016. Most patients (83%) had a contraindication to OAC, and 72% had a history of major bleeding. Successful device implantation was achieved in 99%, and major adverse events occurred in 3.2% of patients. Only a minority of patients (<12%) received short-term OAC after LAA occlusion. Twenty-nine events were observed in 27 patients, corresponding to a 2.9% annualized rate of ischemic stroke, a substantial reduction in the expected ischemic event rate. An important related study was conducted by Nielsen-Kudsk et al. 48 This study followed 151 patients with documented intracranial hemorrhage who had an LAA occlusion with the ACP and Amulet devices. The long-term outcomes of these patients were compared with 151 propensity scoreematched patients who received standard medical therapy (69% OAC; 31% antiplatelet therapy only). Patients treated with LAA occlusion had a lower risk of the composite end point of all-cause mortality, ischemic stroke, and major bleeding than did patients treated with standard care (53. Although the Amulet device is further along in development, several other devices (eg, LAmbre Device, Lifetech, and WaveCrest, Coherex Medical) stand poised to launch clinical trials in the next few years. Extra-cardial approaches to LAA occlusion are also being explored both with percutaneous (LARIAT system, SentreHEART) and surgical (AtriClip, AtriCure) devices. 49, 50 CONCLUSION Oral anticoagulation continues to be the mainstay stroke prevention strategy for patients with nonvalvular AF. Although the advent of DOACs provided similar or better stroke protection compared with warfarin, they did not eliminate the bleeding risks, substantial costs, and nonadherence issues associated with lifelong anticoagulation. In contrast, LAA occlusion has emerged as a feasible alternative stroke prevention strategy to lifelong anticoagulation, with significant reductions in disabling strokes, hemorrhagic strokes, and death. In addition, LAA occlusion compares favorably to OAC with regard to costeffectiveness and patient satisfaction. Ongoing trials studying novel devices, various procedural techniques, and periprocedural antithrombotic regimens, as well as specific highrisk populations, will contribute crucial evidence on this rapidly growing technology, expanding patient options and addressing the significant unmet clinical need of stroke prevention in patients with AF. 
